



CropLife  
EUROPE

# Co-formulant challenges – an industry perspective

Regulatory Conference

7-8<sup>th</sup> March 2023

# Co-formulant challenges

- Annex III issues
- Alternative co-formulant suppliers
- Co-formulant risk assessment

**Common themes in this presentation:** need for harmonized interpretation and implementation by Member State authorities; better collaboration between authorities and with industry.



# Unacceptable co-formulants - implementation

## Key challenges

- Overall “Annex III” implementation has run relatively smoothly in most Member States, with some exceptions.
  - Although has been some “last minute activity” with unrealistic timelines
- Biggest issues are **non-harmonized approaches** to: **Formaldehyde releasers**, Requests for co-formulant “**full compositions**”

## Formaldehyde releasers

- **Only formaldehyde is listed on Annex III.** This means it cannot be used as a co-formulant, it cannot exceed 0.1% as an impurity in a PPP.
- Various unofficial lists have been circulated claiming that the formaldehyde listing on Annex III also means so called “formaldehyde releasers” are also banned. This is an issue because:
  - These **lists have errors** in them – this shows why it is so critical only officially evaluated and harmonized lists from REACH / CLP are used to set up Annex III.
  - There is **no legal mechanism** to “**read-across**” from Annex III to other substances – essential for legal certainty.
- There is no issue with “**unintentional** formaldehyde releasers” – simply comply with Annex III and ensure the concentration of any formaldehyde that may form as an **impurity** does not exceed 0.1%, e.g. stoichiometry (calculation), analytics, etc.

See backup slide for more details

# Annex III - implementation

## Annex III and requests for “full composition”

- In our view requests for full compositions are nearly always unnecessary for the implementation of Annex III: everything on the list is hazardous and should be found declared on the supplier SDS.
  - e.g. Benzene: it would be illegal for a co-formulant solvent supplier to have more than 0.1% benzene in their product and not declare it on the SDS.
- Note: not everything listed on an SDS is a co-formulant – meaning intentionally added by the Authorization holder to the formulation recipe:
  - Impurities are not co-formulants, these are only present unintentionally, and serve no function.
  - Impurities are typically recognisable on an SDS because the concentration is low, specified as a maximum e.g. <0.1%, and is usually hazardous. Extreme example: nobody is using benzene as a co-formulant!

## Challenges for Authorization holders:

- Reliant on co-formulant suppliers to respond to Members State requests, and have no means to control or check compliance with imposed deadlines.
- Information deficit – if there is an issue we are “in the dark”

## What are the other impacts of requesting co-formulant “full compositions”?

“Full composition” – includes identification of non-hazardous components.


# Compositions requests – there has to be a better way!

- Simple calculation: Each Co-formulant Supplier of a substance has 10 customers, each Authorization holder has 10 products. 27 Regulators.
- Each **Supplier** must make **2700 notifications** ( $10 \times 10 \times 27$ ) to the Regulators. But each Authorization holder has 2 suppliers for risk mitigation, so each **Regulator** receives **200 notifications**.
- If each Supplier has 10 different co-formulants they sell to Agchem industry: **27 000 notifications to Regulators**.
- This is the “big picture” impact of composition requests

Given that:

- All hazardous substances are already listed on the SDS.
- And the additional composition information is solely on **non-hazardous** substances, or those **below** the classification **threshold**.

In this context, it is worth reflecting on **what is the value** brought by the collection of this additional information?



# Compositions requests – possible improvements

- Rely as much as possible on supplier SDS information – the legal framework is already in place on what to declare, including enforcement options.
- Request additional information only if there is a specific concern.
- For **substances** the “sameness” identity is defined in the Joint Submission REACH registrations. Composition is only really a question for **mixtures** (i.e. often tradename products).
- Short term: Member States can make public a list of co-formulants for which **composition information** has already been obtained, and **no resubmission** is required e.g. approach of Germany, or US EPA. Ideal would be to share between Member States – legal issues?
- Longer term: consider a central confidential composition database?



# Alternative co-formulants suppliers: challenges

## SUPPLY CHAIN DISRUPTION OVERVIEW



- Alternative co-formulant suppliers are not “nice to have” – they are **essential for the security and robustness of European supply chains**.
- A **fast** alternative supplier notification response is essential. A recent CLE member survey found MS response times vary from 2 months to **2 years**.
- Harmonization and certainty of outcome between Member State assessments is absolutely essential for the EU common market.

# Alternative co-formulants suppliers: challenges

- **Different interpretations** of SANCO “non-significant change” guidance, and rejection of alternative co-formulants accepted in other Member States:
  - There appears to be a tendency towards assessing “identical” rather than looking for “equivalent” and accepting some variability, particularly aspects which are not relevant to formulation classification or risk.
  - If an alternative is rejected because of a non-hazardous (confidential) component, the Authorization holders have no predictability.
- Co-formulants which are mixtures:
  - It is very unlikely to have mixtures with  $\geq 3$  components to be identical from different suppliers (this would imply IP infringement...).
  - A **rigid focus on “identical”** will result in **single supplier** situation and **fragile EU supply chains**.
- **Harmonization and certainty of outcome between Member State assessments is absolutely essential.**



# Co-formulant data and risk

- CLE's view is that **REACH generates proportionate & appropriate hazard data** needed for substances (co-formulants), which are then available for use in other vertical legislation e.g. plant protection, cosmetics, etc.
  - **REACH offers an opportunity to manage co-formulants in a harmonized and efficient manner. The same substances are often used in other sectors e.g. cosmetics (OSOA).**
- Empirically, most registered co-formulants tend to be high-volume “commodity chemicals”, with the highest REACH data requirements – recently confirmed by an EFSA survey.
- REACH supplies **long-term / chronic (eco)toxicology hazard data** on the substances used as co-formulants. This can then be used to derive thresholds (DNEL, PNEC) for **REACH** risk assessments, which includes co-formulant use.
- **Regulation 284/2013** allows for testing on co-formulants: in the vast majority of cases this is unnecessary and should be seen as a **last resort**. Note: in practice any such testing would still be fully subject to REACH processes and approvals e.g. inquiry, testing proposals, data sharing, etc.



# Conclusions

- **We need a truly harmonized approach to co-formulant management to support the EU common market, for example:**
  - Formaldehyde releasers, Composition requests, Acceptance of alternative co-formulants
- **Utilize the information from the co-formulant supplier SDS as much as possible**
- **Use REACH processes as much as possible to assess hazard/risk of co-formulants (One-substance One-assessment)**

**Many more stakeholders involved with co-formulants (suppliers, ECHA, etc): a more collaborative approach is needed for efficient co-formulant management**



 **Backup slide**



# Formaldehyde releasers

## Formaldehyde releasers

- “**Intentional** formaldehyde releasers” – substances deliberately used to release formaldehyde, their function and efficacy come from formaldehyde. “**Unintentional** formaldehyde releasers” may degrade to form formaldehyde, but they do not derive their function or efficacy from this.
- **Only formaldehyde is listed on Annex III**: it cannot be used as a co-formulant, it cannot exceed 0.1% as an impurity in a PPP.
- Various unofficial lists have been circulated claiming that the formaldehyde listing on Annex III also means “formaldehyde releasers” are banned. This is an issue because:
  - These **lists have errors** in them – this shows why it is so critical only official harmonized lists from REACH / CLP are used.
  - There is **no legal mechanism** to “**read-across**” from Annex III to other substances – essential for legal certainty.
- Use of *intentional* formaldehyde releasers is **not** defended here – only that Annex III is applied precisely to ensure regulatory certainty, and to avoid mistakes and unjustified loss of products.

## Way forward

- **No changes** needed for “**unintentional** formaldehyde releasers” – simply comply with Annex III and ensure formaldehyde impurity concentrations do not exceed 0.1%, e.g. stoichiometry (calculation), analytics, etc. This is already a CLP classification obligation.
- “*Intentional* formaldehyde releasers” – MS can submit a **CLH proposal to ECHA**, then add to Annex III. See **CLP, Annex VI, Note 8** for already existing examples e.g. CAS 5625-90-1 [Formaldehyde released from N,N'-methylenebis(morpholine)], CAS 70161-44-3, etc.